Akero Therapeutics, Inc., a leading biopharmaceutical company focused on developing transformative treatments for metabolic diseases, unveiled groundbreaking data on its lead product candidate, efruxifermin (EFX), at the prestigious European Association for the Study of the Liver (EASL) Congress 2024 in Milan, Italy.
The company presented a thought-provoking poster and delivered a late-breaking oral presentation, highlighting the remarkable potential of EFX in addressing critical unmet needs in the field of liver diseases. The data showcased the efficacy and safety profile of EFX, garnering significant attention from the scientific community and industry experts attending the congress.
These presentations at EASL 2024 underscore Akero Therapeutics’ commitment to advancing innovative therapies for patients suffering from metabolic disorders, particularly those affecting the liver. With its cutting-edge research and dedication to scientific excellence, Akero Therapeutics continues to position itself at the forefront of developing life-changing treatments in this crucial area of medical need.
